Therapeutics ID Gable – Flashcards
Unlock all answers in this set
Unlock answers| STI Risk Factors | 
  | 
| Uncomplicated Gonorrhea: Clinical Presentation | 
 
  | 
| Complicated Gonorrhea: Clinical Presentation | 
Pelvic Inflammatory Disease Disseminated gonorrhea 
  | 
| Uncomplicated Gonorrhea Treatment: w/o allergies to beta-lactam | 
Ceftriaxone 125 mg IM x 1 dose OR Cefixime 400 mg PO x 1 dose + Azithromycin 1 g x 1 dose  | 
| Uncomplicated Gonorrhea Treatment: With allergies to beta-lactam | 
Azithromycin 2 g PO x 1 dose (emerging resistance) 
  | 
| Complicated Gonorrhea Treatment: Disseminated | 
| Ceftriaxone IV or IM until improvement begins, then Ceftriaxone PO regimen x 7 days | 
| Complicated Gonorrhea Treatment: Pregnancy | 
Cephalosporin OR Azithromycin  | 
| Primary Syphilis: Clinical Presentation | 
Incubation 10-90 days 
 Site of infection External genitalia, perianal region, mouth, throat 
 Signs/Symptoms Chancre sore, regional lymphadenopathy  | 
| Secondary Syphilis: Clinical Presentation | 
Incubation 2-8 weeks Site of Infection Multisystem involvement Signs/Symptoms Pruritic or nonpruritic rash, mucocutaneous lesion, flu-like symptoms  | 
| Latent Syphilis: Clinical Presentation | 
Incubation 4-10 weeks (after secondary) 
 Site of Infection Multisystem involvement (dormant) 
 Signs/Symptoms Asymptomatic  | 
| Tertiary Syphilis: Clinical Presentation | 
Incubation 10-30 years 
 Site of Infection CNS, heart, eyes, bones, joints 
 Signs/Symptoms Cardiovascular syphilis, gumma lesions present, neurosyphilis  | 
| Primary Syphilis: Treatment/Follow up | 
Benzathine PCN G IM 
 RPR at 6 and 12 months  | 
| Secondary Syphilis: Treatment/Follow up | 
Benzathine PCN G IM 
 RPR at 6 and 12 months  | 
| Early Latent Syphilis: Treatment/Follow up | 
Benzathine PCN G IM 
 RPR at 6 and 12 months  | 
| Late Latent Syphilis: Treatment/Follow up | 
Benzathine PCN G IM weekly x 3 weeks 
 OR 
 Aqueous crystalline PCN G IV infusion x 10-14 days 
 RPR at 6, 12, and 24 months  | 
| Neurosyphilis: Treatment/Follow up | 
Benzathine PCN G IM weekly x 3 weeks 
 OR 
 Aqueous crystalline PCN G IV infusion x 10-14 days 
 CSF examination q 6 months until clear  | 
| Jarisch-Herxheimer Reaction | 
  | 
| Primary Syphilis Treatment: PCN Allergic Patients | 
Doxycycline OR Tetracycline OR Ceftriaxone  | 
| Secondary Syphilis Treatment: PCN Allergic Patients | 
Doxycycline OR Tetracycline OR Ceftriaxone  | 
| Early Latent Syphilis Treatment: PCN Allergic Patients | 
Doxycycline OR Tetracycline OR Ceftriaxone  | 
| Late Latent or Unknown Duration Syphilis Treatment: PCN Allergic Patients | 
Doxycycline OR Tetracycline OR Ceftriaxone  | 
| Uncomplicated Chlamydia: Clinical Presentations | 
  | 
| Complicated Chlamydia: Clinical Presentations | 
PID Infertility Reiter Syndrome  | 
| Uncomplicated Chlamydia: Treatment | 
Azithromycin 1 g PO x 1 dose OR Doxycycline 100 mg PO BID x 7 days 
 Abstain from sexual intercourse x 7 days post treatment  | 
| Pelvic Inflammatory Disease: Risk Factors | 
Young Age Use of IUD Poor socioeconomic status  | 
| Pelvic Inflammatory Disease: Clinical Presentations | 
Results from untreated chlamydia or untreated gonorrhea 
 
  | 
| Pelvic Inflammatory Disease: Treatment | 
PO Outpatient Regimens 
 Ofloxacin x 14 days OR Levofloxacin x 14 days 
 + Metronidazole x 14 days 
 OR 
 Ceftriaxone x 1 dose + Doxycycline x 14 days 
 Parenteral Inpatient Regimen 
 Cefoxitin IV + Doxycycline IV  | 
| HSV Cycle | 
  | 
| Genital Herpes: Clinical Presentation | 
  | 
| Genital Herpes: Treatment of First Clinical Episode | 
Palliative (not curative) 
 
 Acyclovir x 7-10 days OR Famciclovir x 7-10 days OR Valacyclovir x 7-10 days 
  | 
| Genital Herpes: Treatment of Recurrent Infections | 
Chronic Suppressive Tx (> 6 episodes/year): 
 Acyclovir OR Famciclovir OR Valacyclovir  | 
| Genital Herpes: Episodic Treatment | 
Acyclovir 400 mg PO TID x 5 days OR Acyclovir 800 mg PO BID x 5 days OR Acyclovir 800 mg PO TID x 2 days OR Famciclovir 125 mg PO TID x 5 days OR Valacyclovir 500 mg PO BID x 5 days OR Valacyclovir 1 g PO QD x 5 days  | 
| Genital Herpes: Resistance to 1st Line Antivirals | 
| Foscarnet | 
| Herpes Antivirals: MOA, AEs | 
MOA 
 AE Famciclovir: N/D, HA, fever, dizziness fatigue Valacyclovir: N/V/D, HA, abdominal pain, dizziness Acyclovir: N/V/D, HA, lethargy, dizziness, rash, nephrotoxicity  | 
| Uncomplicated Trichomoniasis: Clinical Presentation | 
Females: Scant to copious, malodorous vaginal discharge Pruritis 
 Males: Often asymptomatic Urethral discharge (clear to mucopurulent)  | 
| Complicated Trichomoniasis: Clinical Presentation | 
  | 
| Trichomoniasis: Treatment | 
Metronidazole 2 g PO x 1 dose OR 500 mg Po BID x 7 days 
 OR 
 Tinidazole 2 g PO x 1 dose  | 
| Metronidazole: Counseling, AE, CI | 
 AE 
 
 Avoid EtOH: 
  | 
| Tinidazole: Uses, AE | 
 AE 
 
 Avoid EtOH: 
  | 
| Human Papillomavirus 6 is associated with: | 
| Development of genital warts | 
| Human Papillomavirus 11 is associated with: | 
| Development of genital warts | 
| Human Papillomavirus 16 is associated with: | 
| Increased risk of cervical neoplasia | 
| Human Papillomavirus 18 is associated with: | 
| Increased risk of cervical neoplasia | 
| HPV: Treatments | 
Cryotherapy with liquid nitrogen or surgical removal for external warts 
 Patient Applied Therapy: Podofilox sol'n or gel Imiquimod cream  | 
| Gardasil: Uses | 
 ;  | 
| Gardasil: AE | 
  | 
| Expedited Partner Therapy | 
 
 Azithromycin OR Cefixime  | 
| Herpes Simplex Virus (HSV) - 1 | 
| Oropharyngeal disease | 
| Herpes Simplex Virus (HSV) - 2 | 
| Genital disease |